These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 25572028

  • 1. Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.
    Deo R, Katz R, de Boer IH, Sotoodehnia N, Kestenbaum B, Mukamal KJ, Chonchol M, Sarnak MJ, Siscovick D, Shlipak MG, Ix JH.
    Am J Kidney Dis; 2015 Jul; 66(1):40-6. PubMed ID: 25572028
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
    Edmonston D, Wojdyla D, Mehta R, Cai X, Lora C, Cohen D, Townsend RR, He J, Go AS, Kusek J, Weir MR, Isakova T, Pencina M, Wolf M, CRIC Study Investigators.
    Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
    [Abstract] [Full Text] [Related]

  • 6. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
    Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH.
    Clin J Am Soc Nephrol; 2014 Jun 06; 9(6):1049-58. PubMed ID: 24677555
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
    Smith K, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R, Wolf M, Januzzi J.
    Am J Kidney Dis; 2013 Jan 06; 61(1):67-73. PubMed ID: 22883134
    [Abstract] [Full Text] [Related]

  • 9. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I, Brosius F, Gadegbeku C, Gipson D, Hawkins J, Himmelfarb J, Ju W, Kestenbaum B, Kretzler M, Robinson-Cohen C, Steigerwalt S, Bansal N.
    Am J Kidney Dis; 2018 Oct 06; 72(4):519-528. PubMed ID: 29866459
    [Abstract] [Full Text] [Related]

  • 10. Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline.
    Drew DA, Katz R, Kritchevsky S, Ix JH, Shlipak MG, Newman AB, Hoofnagle A, Fried L, Sarnak MJ, Gutierrez OM.
    Am J Nephrol; 2018 Oct 06; 47(4):242-250. PubMed ID: 29621752
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.
    BMJ Open; 2017 Aug 23; 7(8):e016528. PubMed ID: 28838895
    [Abstract] [Full Text] [Related]

  • 13. Sudden cardiac death in non-dialysis chronic kidney disease patients.
    Caravaca F, Chávez E, Alvarado R, García-Pino G, Luna E.
    Nefrologia; 2016 Aug 23; 36(4):404-9. PubMed ID: 27267917
    [Abstract] [Full Text] [Related]

  • 14. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M, CRIC Study Investigators.
    Kidney Int; 2017 Mar 23; 91(3):711-719. PubMed ID: 28017325
    [Abstract] [Full Text] [Related]

  • 15. Global Electric Heterogeneity Risk Score for Prediction of Sudden Cardiac Death in the General Population: The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.
    Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, Henrikson CA, Sotoodehnia N, Biering-Sørensen T, Agarwal SK, Siscovick DS, Post WS, Solomon SD, Buxton AE, Josephson ME, Tereshchenko LG.
    Circulation; 2016 Jun 07; 133(23):2222-34. PubMed ID: 27081116
    [Abstract] [Full Text] [Related]

  • 16. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML.
    JAMA Cardiol; 2018 Jun 01; 3(6):473-480. PubMed ID: 29710336
    [Abstract] [Full Text] [Related]

  • 17. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
    Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J, Jarolim P.
    JACC Heart Fail; 2015 Oct 01; 3(10):829-39. PubMed ID: 26450001
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study.
    Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B.
    Hypertension; 2011 Dec 01; 58(6):1021-8. PubMed ID: 22068871
    [Abstract] [Full Text] [Related]

  • 19. Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.
    Panwar B, Judd SE, Wadley VG, Jenny NS, Howard VJ, Safford MM, Gutiérrez OM.
    JAMA Cardiol; 2018 Apr 01; 3(4):318-325. PubMed ID: 29516098
    [Abstract] [Full Text] [Related]

  • 20. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E, Thodis E, Arsos G, Pasadakis P, Panagoutsos S, Papadopoulou D, Papagianni A.
    Kidney Blood Press Res; 2020 Apr 01; 45(6):900-915. PubMed ID: 33040068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.